
Pawan Saharan
Founder CEO Biomix Network Inc. USA, E-mail: drpawan@biomix.in

Pharmacovigilance otherwise known as drug safety, is the pharmacological science relating to the collection, detection, assessment, monitoring, and prevention of adverse effects with products. As such, pharmacovigilance heavily focuses on adverse drug reactions, or ADRs, which are defined as any response to a drug which is noxious and unintended, including lack of efficacy. Medication errors such as overdose, and misuse and abuse of a drug as well as drug exposure during pregnancy and breastfeeding, are also of interest, even without an adverse event, because they may result in an adverse drug reaction. Information received from patients and healthcare providers via pharmacovigilance agreements as well as other sources such as the medical literature, plays a critical role in providing the data necessary for pharmacovigilance to take place. In order to market or to test a pharmaceutical product in most countries, adverse event data received by the license holder must be submitted to the local drug regulatory authority.

Expert Level (Scientific Service Achievement Award)

The Achievement award is designed to recognize sustained, exceptional performance and/or significant contributions of the individuals who have made splendid contributions in the field of Pharmacovigilance. The applicants should have minimum of 20+ years of experience in the relative field including performance or project goals above and beyond normal performance expectations in public or private sector. The applicants are expected to have a highly committed passion and should take lead in researching the current trends and developments towards the related subjects. The applicants can be nominated through online.

Professional Level (The Research Contribution Award)

The Research Contribution Award aims to recognized renowned professional for their excellence in research in the area of Pharmacovigilance & Drug Safety. The applicants should have 10+ years in area of Pharma with their outstanding achievements. Part-time research experience would be counted as pro-rata. It is calculated starting from the date when you obtained the (first) degree entitling you to embark on a doctorate (either in the country in which the degree was obtained or in the country in which the researcher is recruited), even if a doctorate was never started or envisaged. The applicants can be nominated through online.

Pharmacovigilance Conference 2020 supported by the organizing committee network of renowned scientific and professional expert such as Stanley Cohan, Providence Multiple Sclerosis Center, USA, Mircea Ciuca, Head - Global Clinical Safety and Pharmacovigilance, Switzerland, UK, Heyam Saad Ali, Professor Dubai Pharmacy College, UAE, Amalia Levy, Ben-Gurion University, Israel provided a platform for collaboration among colleagues, vendors, and academia to reveal new innovations, solutions, ideas, and emerging technologies in Pharmacovigilance & Drug Safety.

The GDP is projected to rise by 2.5 percent in 2019, 1.9 percent in 2020 and 1.8 percent in 2021. The Pharma industry will be source of strength, with growth of 2.5 percent in 2019 and 3.0 percent in 2020. In fact, Pharma industry growth will exceed that of the US economy through 2024.


Contact Details:
Daniel Scotch
Conference Manager | Pharmacovigilance 2020
Send a mail to pharmacovigilance@brainstormingmeetings.com
Phone no: +448000148923
WhatsApp No: +44-113-320-6997